Failure to Follow Through on Psychotropic Medication Reviews
Summary
The facility failed to follow through on consultant pharmacist medication regimen review recommendations for 3 of 5 residents reviewed for chemical restraints. The deficiency involved failure to notify the physician and document responses or medication changes related to antipsychotic, antianxiety, and other psychotropic medications, as well as delayed monitoring and lab follow-up tied to those medications. One resident was admitted with diagnoses including acute respiratory failure, A-fib, CKD, CHF, osteoarthritis, obesity, anemia, generalized anxiety disorder, and major depressive disorder. The resident’s record showed orders for escitalopram, memantine, and trazodone for insomnia. Pharmacy notes dated earlier in the year stated that trazodone was due for hypnotic drug and dose evaluation and later referenced physician recommendation, but the facility was unable to provide the pharmacist’s recommendation, the physician’s response, or any medication change. A second resident was admitted with dementia, generalized anxiety disorder, and schizophrenia and had orders for fluphenazine, hydroxyzine, and memantine. Pharmacy notes requested quarterly abnormal movement monitoring for antipsychotic therapy and recommended lab review, including TSH, HbA1c, CMP, and CBC. The resident’s AIMS was completed several months after the pharmacy recommendation, and the requested labs were not drawn until months later. The facility could not provide the pharmacist’s recommendation or the physician’s response. A third resident had diagnoses including cerebral infarction, hemiplegia, schizophrenia, anxiety disorder, bipolar disorder, dementia, and depression, with orders for lorazepam, mirtazapine, olanzapine, and hydroxyzine. Pharmacy notes requested quarterly abnormal movement monitoring for antipsychotic therapy and specifically questioned the routine use of hydroxyzine, asking that the risks and benefits of continued therapy be reviewed and documented. The resident’s AIMS was not completed until months later, labs were drawn months after the pharmacy recommendation, and the facility was unable to provide the pharmacist’s recommendation, the physician’s response, or any medication change.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.